6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
Key Takeaways
Genitourinary Syndrome of Menopause (GSM) results from estrogen deficiency causing thinning of the vulvovaginal epithelium, loss of rugae, cellular glycogen depletion, loss of protective Lactobacillus species, and vaginal pH elevation (>5.0).
First-line pharmacotherapy for symptomatic GSM refractory to non-hormonal moisturizers and lubricants is low-dose local vaginal estrogen; systemic absorption is minimal and does NOT require opposing progestogen even in women with an intact uterus.
Routine osteoporosis screening with central Dual-Energy X-ray Absorptiometry (DEXA) is universally recommended for all women aged 65 and older, and for postmenopausal women under 65 at increased risk on a formal clinical risk assessment (USPSTF 2025).
Osteoporosis is diagnosed by a DEXA T-score of <= -2.5 at the lumbar spine, femoral neck, or total hip, or by the clinical occurrence of a low-trauma fragility fracture regardless of bone mineral density.
First-line pharmacologic treatment for osteoporosis consists of oral bisphosphonates (alendronate, risedronate), which require strict administration on an empty stomach with plain water remaining upright for 30 minutes; denosumab requires prompt transition to a bisphosphonate upon cessation to prevent rebound vertebral fractures.
Genitourinary Syndrome of Menopause (GSM): Pathophysiology
Genitourinary Syndrome of Menopause (GSM) is a progressive hypoestrogenic condition affecting the vulva, vagina, urethra, and bladder. Unlike vasomotor symptoms, GSM does not improve spontaneously and affects up to 50% to 70% of postmenopausal women.
Estrogen Depletion & Vaginal Dysbiosis
The lower urogenital tract shares an embryological origin from the urogenital sinus and has a high concentration of estrogen receptors (ER-alpha and ER-beta). Hypoestrogenism triggers distinct microenvironmental changes:
- Epithelial Atrophy: Stratified squamous epithelium thins from 30–40 layers to 3–5 layers of basal/parabasal cells. Submucosal capillary networks regress and collagen hyalinizes, causing loss of vaginal rugae, mucosal pallor, decreased distensibility, and introital stenosis.
- Glycogen Depletion: Thinning epithelium depletes cellular glycogen, the primary metabolic substrate for commensal Lactobacillus species.
- pH Elevation & Dysbiosis: Diminished Lactobacillus colonization impairs lactic acid production, causing vaginal pH to rise from an acidic 3.8–4.5 to an alkaline pH >5.0 (frequently 6.0–7.5).
- Loss of Colonization Resistance: Elevated pH allows proliferation of enteric pathogens (Escherichia coli, Klebsiella, Enterococcus), predisposing to dyspareunia, secondary vaginitis, and recurrent postmenopausal urinary tract infections (UTIs).
Clinical Spectrum & Stepwise Management of GSM
Clinical Presentation
- Vulvovaginal: Vaginal dryness, burning, pruritus, dyspareunia, introital tearing, postcoital bleeding, mucosal petechiae, labial resorption, and clitoral phimosis.
- Urinary: Dysuria, urgency, frequency, nocturia, and recurrent UTIs (≥2 culture-proven UTIs in 6 months or ≥3 in 12 months).
Stepwise Management Ladder
| Tier | Agent | Regimen | Clinical Practice Pearls |
|---|---|---|---|
| Tier 1: Non-Hormonal | Vaginal Moisturizers & Lubricants | • Moisturizers: Polycarbophil or hyaluronic acid 2–3 times weekly. • Lubricants: Water- or silicone-based applied prior to coitus. | First-line for mild symptoms or hormonal contraindications; improves hydration without reversing underlying tissue atrophy. |
| Tier 2: First-Line Pharmacotherapy | Low-Dose Local Vaginal Estrogens | • Estradiol tablet (10 mcg): Daily x 2 weeks, then twice weekly. • Estradiol cream 0.01% (0.5 g): Daily x 1–2 weeks, then twice weekly. • Estradiol ring (Estring 2 mg): Replaced every 90 days. | Restores rugae, glycogen, and lactobacilli; lowers pH and cuts recurrent UTIs by >50%. Systemic absorption is negligible (<10–20 pg/mL); opposing progestogen is NOT required, even with an intact uterus. |
| Tier 3: Alternative Therapies | Intravaginal Prasterone & Oral Ospemifene | • Prasterone (DHEA 6.5 mg ovule): Daily at bedtime. • Ospemifene (60 mg tablet): Daily with food. | • Prasterone: Local intracellular conversion to estrogens/androgens without raising serum steroids. • Ospemifene: Oral SERM approved for moderate-to-severe dyspareunia. |
Note
In breast cancer survivors with refractory GSM, low-dose local vaginal estrogens or prasterone may be considered after shared decision-making and written oncologic clearance, as systemic absorption rarely exceeds postmenopausal baseline levels.
Postmenopausal Osteoporosis: Bone Remodeling Pathophysiology
Bone remodeling balances osteoclast resorption with osteoblast matrix synthesis:
- Estrogen promotes osteoclast apoptosis and stimulates osteoprotegerin (OPG) production by osteoblasts. OPG acts as a decoy receptor binding RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), preventing it from activating its receptor (RANK) on osteoclasts.
- Postmenopausal estrogen loss removes this brake: OPG levels fall, and RANKL activity surges, driving unchecked osteoclastogenesis and prolonging osteoclast lifespan.
- This uncoupling accelerates bone loss at rates of 1% to 5% per year during the first 5 to 7 years post-menopause, predisposing to fragility fractures of the vertebrae, femoral neck, and distal radius (Colles fracture).
Screening Guidelines & DEXA Diagnostic Criteria
The goal of screening is preventing low-trauma fragility fractures (fractures occurring from a fall from standing height or less).
Screening Guidelines
- Universal Screening: Central Dual-Energy X-ray Absorptiometry (DEXA) of the femoral neck and lumbar spine is indicated for all women aged 65 and older.
- Targeted Screening (<65 Years): Indicated for postmenopausal women under 65 with major fracture risk factors: BMI <20 kg/m², current smoking, parental hip fracture, chronic glucocorticoids (≥5 mg prednisone daily for ≥3 months), rheumatoid arthritis, or increased risk on a validated tool such as FRAX or OST (the 2025 USPSTF statement names no single FRAX cutoff).
T-Score Diagnostic Classifications (Central DEXA)
BMD is reported as a T-score, comparing patient bone mineral density to healthy young adult reference norms:
| Classification | DEXA T-Score Threshold | Clinical Significance |
|---|---|---|
| Normal | T-score ≥ -1.0 | Normal bone density within 1 SD of reference mean. |
| Osteopenia (Low Bone Mass) | T-score between -1.0 and -2.5 | Mild-to-moderate loss; calculate FRAX to determine treatment eligibility. |
| Osteoporosis | T-score ≤ -2.5 | Marked loss at lumbar spine, femoral neck, or total hip. |
| Clinical Osteoporosis | Low-trauma fragility fracture | Diagnosed clinically regardless of T-score (even if osteopenic or normal). |
Tip
A Z-score ≤ -2.0 (compared to age-matched norms) indicates secondary osteoporosis, warranting evaluation for hyperparathyroidism, celiac disease, multiple myeloma, or severe vitamin D deficiency.
Comprehensive Osteoporosis Management & Pharmacotherapy
Non-Pharmacologic Foundations
- Elemental Calcium: 1,200 mg daily (dietary preferred). If supplements are used, calcium carbonate requires gastric acid (take with meals); calcium citrate is absorbed acid-independently and is preferred with PPI therapy or achlorhydria.
- Vitamin D3: 800 to 1,000 IU daily (target serum 25-hydroxyvitamin D ≥30 ng/mL).
- Lifestyle: Progressive weight-bearing/resistance exercise, smoking cessation, and home fall prevention.
Pharmacologic Treatment Indications
Treatment is indicated for:
- T-score ≤ -2.5 at femoral neck, total hip, or lumbar spine.
- Low-trauma hip or vertebral fragility fracture regardless of T-score.
- Osteopenia with FRAX 10-year risk of major osteoporotic fracture ≥20% or hip fracture ≥3%.
Pharmacologic Classes
1. First-Line Antiresorptive: Oral Bisphosphonates
- Agents: Alendronate (70 mg weekly) or risedronate (35 mg weekly).
- Administration Rules: Oral bioavailability is <1% and blocked by food. Patients must take the drug first thing in the morning with 8 oz plain water, remain upright for ≥30 minutes, and defer all food/medications for ≥30 minutes to prevent chemical esophagitis.
- Rare Risks: Atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ).
- Drug Holiday: Consider a holiday after 3 to 5 years of oral therapy (or 3 years of IV zoledronic acid 5 mg annual infusion) in low-to-moderate risk patients.
2. RANKL Inhibitor: Denosumab (Prolia)
- Dosing: 60 mg subcutaneous injection every 6 months.
- Critical Warning (Rebound Fractures): Denosumab does not bind bone matrix. Discontinuation triggers rapid bone turnover rebound and severe multiple vertebral fractures. Denosumab must NEVER be stopped without immediately transitioning to an alternative bisphosphonate.
3. Anabolic Agents (Bone Builders)
- Teriparatide (PTH 1-34) & Abaloparatide (PTHrP): Daily subcutaneous injections for up to 2 years for severe osteoporosis (T-score ≤ -3.0 or prior fracture); must be followed by an antiresorptive agent.
- Romosozumab: Sclerostin antibody stimulating bone formation while suppressing resorption; monthly subcutaneous injections for 12 months.
A 63-year-old postmenopausal female presents to the clinic complaining of worsening vaginal burning, dryness, and severe dyspareunia that has prevented sexual intercourse for the past 6 months. She also reports a 9-month history of recurrent urinary tract infections, having been treated for 3 separate culture-confirmed Escherichia coli infections. Her last menstrual period was at age 51. She has an intact uterus. Pelvic examination reveals pale, shiny, thin vaginal mucosa with absent rugae, petechiae, and a vaginal pH of 6.2. Wet mount microscopy is negative for clue cells, yeast, and trichomonads, but demonstrates numerous parabasal cells. Over-the-counter vaginal moisturizers have failed to provide relief. What is the most appropriate first-line pharmacotherapeutic management plan for this patient?
Initiate daily oral conjugated equine estrogens (0.625 mg) combined with continuous oral medroxyprogesterone acetate (2.5 mg).
Prescribe daily oral nitrofurantoin 100 mg postcoitally for UTI prophylaxis and advise pelvic floor physical therapy.
Prescribe low-dose vaginal 17-beta estradiol tablets (10 mcg) twice weekly without the addition of a progestogen.
Prescribe low-dose vaginal 17-beta estradiol tablets (10 mcg) twice weekly combined with oral micronized progesterone 100 mg daily.
A 67-year-old female presents for a routine wellness evaluation. A screening central DEXA scan demonstrates a bone mineral density T-score of -2.8 at the lumbar spine and -2.4 at the femoral neck. Her laboratory evaluation reveals normal renal function, serum calcium, and 25-hydroxyvitamin D levels. She is diagnosed with postmenopausal osteoporosis and prescribed oral alendronate 70 mg once weekly. Which administration instruction is essential to prevent severe medication-related adverse effects and ensure drug bioavailability?
Take the tablet with an evening meal high in dietary fat to optimize absorption, and take calcium supplements at the same time.
Take it on waking with 8 oz of plain water, stay upright for 30 minutes, and wait 30 minutes before eating or other drugs.
Crush the tablet and dissolve it in fruit juice or milk to minimize gastric acidity, then lie down for 30 minutes.
Take the tablet at bedtime with a full glass of milk to ensure adequate calcium co-administration.
A 64-year-old female with severe postmenopausal osteoporosis has been receiving subcutaneous denosumab 60 mg every 6 months for the past 3 years. Her latest central DEXA scan shows excellent therapeutic response, with her lumbar spine T-score improving from -3.2 to -2.3. The patient asks whether she can discontinue the denosumab injections now that her bone density has reached the osteopenic range. What critical clinical guidance must the WHNP provide regarding the discontinuation of denosumab?
Do not stop denosumab without a bisphosphonate or other antiresorptive, because rebound bone loss and vertebral fractures follow.
She may safely stop denosumab for a 2-year 'drug holiday' without other therapy because the drug is retained in bone.
Denosumab should be replaced by daily oral calcium and vitamin D supplementation alone, with a repeat DEXA scan scheduled in 3 years.
The injection interval should be gradually lengthened to once every 12 months for 2 years before stopping it completely.
Sections you finish are checked off in the contents.